Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan;10(1):35-37.
doi: 10.21037/jtd.2017.11.126.

Why did VALIDATE-SWEDEHEART not validate the results of HORIZONS?

Uwe Zeymer  1
Affiliations
Editorial

Why did VALIDATE-SWEDEHEART not validate the results of HORIZONS?

Uwe Zeymer. J Thorac Dis. 2018 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: AstraZeneca, B. Braun, BMS, BoehringerIngelheim, BayerHealtcare, Correvio, Daiichi Sankyo, Eli Lilly, Medtronic, Medicines Company, MSD, Novartis, Pfizer, Sanofi.

Figures

Figure 1
Figure 1
Major bleeding complications in randomized trials comparing unfractionated heparin and bivalirudin in patients undergoing primary PCI for STEMI according to the rate of use of GP IIb/IIIa inhibitors in the UFH groups. UFH, unfractionated heparin; GP IIb/IIIa inhibitors, glycoprotein IIb/IIIa receptor inhibitors; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.
Figure 2
Figure 2
All cause 30-day mortality in randomized trials comparing UFH and bivalirudin in patients undergoing primary PCI for STEMI. UFH, unfractionated heparin; GP IIb/IIIa inhibitors, glycoprotein IIb/IIIa receptor inhibitors; PCI, percutaneous coronary intervention; STEMI, ST segment elevation myocardial infarction.
See this image and copyright information in PMC

Comment on

  • Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
    Erlinge D, Omerovic E, Fröbert O, Linder R, Danielewicz M, Hamid M, Swahn E, Henareh L, Wagner H, Hårdhammar P, Sjögren I, Stewart J, Grimfjärd P, Jensen J, Aasa M, Robertsson L, Lindroos P, Haupt J, Wikström H, Ulvenstam A, Bhiladvala P, Lindvall B, Lundin A, Tödt T, Ioanes D, Råmunddal T, Kellerth T, Zagozdzon L, Götberg M, Andersson J, Angerås O, Östlund O, Lagerqvist B, Held C, Wallentin L, Scherstén F, Eriksson P, Koul S, James S. Erlinge D, et al. N Engl J Med. 2017 Sep 21;377(12):1132-1142. doi: 10.1056/NEJMoa1706443. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844201 Clinical Trial.

References

    1. Zeymer U, Rao SV, Montalescot G. Anticoagulation in coronary intervention. Eur Heart J 2016;37:3376-85. 10.1093/eurheartj/ehw061 - DOI - PubMed
    1. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011;32:1854-64. 10.1093/eurheartj/ehr204 - DOI - PubMed
    1. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63. 10.1001/jama.289.7.853 - DOI - PubMed
    1. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16. 10.1056/NEJMoa062437 - DOI - PubMed
    1. Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST elevation myocardial infarction. N Engl J Med 2011;365:1980-89. 10.1056/NEJMoa1109596 - DOI - PubMed

LinkOut - more resources